Trial | NCT00162461  Report issue

Title

Evaluation of CYP2C9 Activity
The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity In-vivo

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    phenytoin ...

  • Study Participants

    1200
The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9.

The purpose of the present study is:

To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity
To correlate phenytoin metabolic ratio with CYP2C9 genotype
To study the frequency distribution of CYP2C9 activity in-vivo
Study Started
Aug 31
1998
Primary Completion
Dec 31
2020
Anticipated
Study Completion
Dec 31
2020
Anticipated
Last Update
Jun 12
2018

Drug Phenytoin single dose (300 mg)

Phenytoin Experimental

Criteria 

Inclusion Criteria:

Age range of 20-50 years old
Absence of significant disease states

Exclusion Criteria:

The presence of significant disease states
The use of drugs (including birth control pills)
No Results Posted